Biodexa Pharmaceuticals (BDRX) Interest Expenses (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Interest Expenses data on file, last reported at $360192.3 in Q2 2025.

• For the quarter ending Q2 2025, Interest Expenses changed N/A year-over-year to $360192.3; the trailing twelve-month figure through Dec 2025 stood at $297300.7 (up 428.79% YoY), and the FY2025 full-year result was $301938.9, up 42.57% from the prior year.
• Interest Expenses climbed to $360192.3 in Q2 2025, from -$62891.6 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $360192.3 in Q2 2025 to a low of -$216759.6 in Q3 2021.
• A 5-year average of -$30730.0 and a median of -$29681.4 in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses slumped 882.41% in 2021 and surged 86.61% in 2022, its largest moves.
• Tracing BDRX's Interest Expenses over 5 years: stood at -$210289.7 in 2021, then surged by 86.61% to -$28150.3 in 2022, then rose by 2.2% to -$27530.0 in 2023, then slumped by 128.45% to -$62891.6 in 2024, then soared by 672.72% to $360192.3 in 2025.
• Business Quant data shows BDRX's Interest Expenses at $360192.3 in Q2 2025, -$62891.6 in Q4 2024, and -$27530.0 in Q2 2023.